Drug
Gossypol-acetic acid clinical trials
Also written R-(-)-gossypol acetic acid.
A product of Gossypol acetic acid; its studies count on that page too.
- studies test it
- 21
- open now
- 1
- in phase 3
- 0
- first study started
- 2005
Keep track of what changes. Save the Gossypol-acetic acid studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
21 studies that test it; most in 2006 (4)
| Year | Studies |
|---|---|
| 2005 | 2 |
| 2006 | 4 |
| 2007 | 4 |
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 2 |
| 2012 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 17
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 11
Ascenta Therapeutics (9) · National Cancer Institute (NCI) (6) · Mayo Clinic (2) · University of Michigan Rogel Cancer Center (2) · AbClon (1) · University of Alabama at Birmingham (1)
Often tested with
Tested in the same studies.
Isosorbide (14) · Anti-CD19 CAR T Cells AT101 (14) · Lenalidomide (2) · Docetaxel (2) · Dexamethasone (1) · Cisplatin (1) · Etoposide (1) · Paclitaxel (1)
Studies
Open first, then newest update. How each study uses Gossypol-acetic acid is read from its arms, and is right about nine times in ten.
Testing it · 21
- Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's LymphomaRecruitingPhase 1/2AbClonNCT05338931Written as AT101(Anti-CD19 Chimeric Antigen Receptor T cell)
- Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple MyelomaCompletedPhase 1Mayo ClinicNCT02697344Written as R-(-)-Gossypol Acetic Acid
- Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal CancerCompletedPhase 2University of Michigan Rogel Cancer CenterNCT01633541Written as AT-101
- Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic LeukemiaTerminatedPhase 1/2Mayo ClinicNCT01003769Written as R-(-)-Gossypol Acetic Acid
- Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma MultiformeCompletedPhase 2National Cancer Institute (NCI)NCT00540722Written as R-(-)-gossypol acetic acid
- A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and NeckTerminatedPhase 2University of Michigan Rogel Cancer CenterNCT01285635Written as AT-101
- Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung CancerWithdrawnPhase 1University of Alabama at BirminghamNCT00934076Written as Tarceva plus AT-101
- R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT00666666Written as AT-101
- R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung CancerCompletedPhase 2National Cancer Institute (NCI)NCT00773955Written as R-(-)-gossypol acetic acid
- Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By SurgeryCompletedPhase 2National Cancer Institute (NCI)NCT00848016Written as R-(-)-gossypol acetic acid
- R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung CancerCompletedPhase 1National Cancer Institute (NCI)NCT00544596Written as R-(-)-gossypol acetic acid
- Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedPhase 1National Cancer Institute (NCI)NCT00891072Written as R-(-)-gossypol acetic acid
- An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction CancerTerminatedPhase 1/2Ascenta TherapeuticsNCT00561197Written as AT-101
- Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell MalignanciesCompletedPhase 2Ascenta TherapeuticsNCT00275431Written as AT-101
- Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPCCompletedPhase 1/2Ascenta TherapeuticsNCT00286793Written as AT-101
- A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)CompletedPhase 2Ascenta TherapeuticsNCT00571675Written as AT-101, prednisone and docetaxel
- A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung CancerCompletedPhase 2Ascenta TherapeuticsNCT00544960Written as AT-101 and docetaxel
- Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's LymphomaCompletedPhase 2Ascenta TherapeuticsNCT00440388Written as AT-101
- A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate CancerCompletedPhase 1/2Ascenta TherapeuticsNCT00286806Written as AT-101
- Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung CancerCompletedPhase 1/2Ascenta TherapeuticsNCT00397293Written as AT-101
Codes
What other systems call Gossypol-acetic acid · ClinicalTrials.gg INT018109
- UNII (FDA) U9GNI6VT5NGOSSYPOL ACETIC ACID, (R)-Confirmed FDA, Wikidata
- Wikidata Q72480824Gossypol-acetic acidConfirmed FDA, Wikidata
- NCI Thesaurus C78348R-(-)-Gossypol Acetic AcidOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | U9GNI6VT5N | GOSSYPOL ACETIC ACID, (R)- | Confirmed FDA, Wikidata |
| Wikidata | Q72480824 | Gossypol-acetic acid | Confirmed FDA, Wikidata |
| NCI Thesaurus | C78348 | R-(-)-Gossypol Acetic Acid | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.